Reducing the price of treatment for multidrug-resistant tuberculosis through the global drug facility;Réduction du prix du traitement pour soigner la tuberculose multirésistante aux médicaments par le biais du Dispositif mondial d’approvisionnement en medicaments;Reducir el precio del tratamiento para la tuberculosis multirresistente mediante el servicio farmacéutico mundial

Bulletin of the World Health Organization

Volumn 93, Issue 4, 2015, Pages 279-282

  Lunte, Kaspars ^a   Cordier Lassalle, Thierry ^b   Keravec, Joel ^a  

^a Stop TB Partnership   (Switzerland)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

COST ANALYSIS; DISEASE TREATMENT; DRUG; GLOBAL PERSPECTIVE; HEALTH EXPENDITURE; INCENTIVE; PRICING POLICY; QUALITY CONTROL; STANDARD (REGULATION); TUBERCULOSIS;

ARTICLE; COST CONTROL; DRUG COST; DRUG MANUFACTURE; HEALTH CARE FACILITY; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; COMMERCIAL PHENOMENA; DRUG INDUSTRY; ECONOMICS; HEALTH CARE DELIVERY; HEALTH PROMOTION; PROCEDURES; SUPPLY AND DISTRIBUTION; TUBERCULOSIS, MULTIDRUG-RESISTANT; UNITED STATES;

ANTITUBERCULAR AGENTS; COMMERCE; DRUG COSTS; DRUG INDUSTRY; HEALTH PROMOTION; HEALTH SERVICES ACCESSIBILITY; HUMANS; TUBERCULOSIS, MULTIDRUG-RESISTANT; UNITED STATES;

EID: 84926024019     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.14.145920     Document Type: Article

References (8)

1. Multidrug-resistant tuberculosis (MDR-TB), 2014 update. Geneva: World Health Organization; 2014. Available from: http://www.who.int/tb/challenges/mdr/mdr_tb_factsheet.pdf?ua=1 [cited 2015 Jan 6].
2. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010 Sep;10(9):621–9. doi: http://dx.doi.org/10.1016/S1473-3099(10)70139-0 PMID: 20797644
3. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al.; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9(8):e1001300. doi: http://dx.doi.org/10.1371/journal.pmed.1001300 PMID: 22952439
4. The Global Plan to Stop TB. 2011–2015. Geneva: Stop TB Partnership; 2011. Available from: http://www.stoptb.org/assets/documents/global/plan/TB_GlobalPlanToStopTB2011-2015.pdf [cited 2015 Jan 6].
5. Hoen’t EF, Hogerzeil HV, Quick JD, Sillo HB. A quiet revolution in global public health: the World Health Organization’s Prequalification of Medicines Programme. J Public Health Policy. 2014 May;35(2):137–61. doi: http://dx.doi.org/10.1057/jphp.2013.53 PMID: 24430804
6. Bate R, Jensen P, Hess K, Mooney L, Milligan J. Substandard and falsified anti-tuberculosis drugs: a preliminary field analysis. Int J Tuberc Lung Dis. 2013 Mar;17(3):308–11. doi: http://dx.doi.org/10.5588/ijtld.12.0355 PMID: 23321423
7. Bate R, Jin GZ, Mathur A, Attaran A. Poor quality drugs and global trade: a pilot study. NBER Working Paper No. w20469. Rochester: Social Science Research Network; 2014. Available from: http://ssrn.com/abstract=2492979 [cited 2015 Jan 6].
8. Arinaminpathy N, Cordier-Lassalle T, Vijay A, Dye C. The Global Drug Facility and its role in the market for tuberculosis drugs. Lancet. 2013 Oct 19;382(9901):1373–9. doi: http://dx.doi.org/10.1016/S0140-6736(13)60896-X PMID: 23726162